Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Andrew Sallman, James M. Foran, Justin M. Watts, Eytan Stein, Stéphane De Botton, Amir Tahmasb Fathi, Gabrielle T. Prince, Richard M. Stone, Prapti Arvind Patel, Gail J. Roboz, Martha Lucia Arellano, Harry Paul Erba, Arnaud Pigneux, Praneeth Baratam, Xavier G. Thomas, Xiaofei Bai, Stephanie M. Kapsalis, Guillermo Garcia-Manero, Courtney Denton Dinardo
Institutions: Moffitt Cancer Center, Mayo Clinic, Mayo Clinic in Florida, University of Miami, Sylvester Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, Harvard University, Massachusetts General Hospital, Johns Hopkins Hospital, Dana-Farber Cancer Institute, The University of Texas Southwestern Medical Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Weill Cornell Medical Center, Emory University, Winship Cancer Institute, Duke University, Centre Hospitalier Universitaire de Bordeaux, Medical University of South Carolina, Hôpital Lyon Sud, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286298880